30 closest matches · ranked by relevance
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Cholangiocarcinoma · Stage III Gallbladder Cancer AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7
Primary: 16-Week Progression-free Survival (PFS) Rate — 32.0 percentage of patients
Stage III Distal Bile Duct Cancer AJCC v8 · Stage III Gallbladder Cancer AJCC v8 · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Overall Survival (OS) — 14.0; 13.6 months — p=0.41
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Biliary Tract Neoplasms
Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants
Biliary Tract Cancer · Cholangiocarcinoma · Gallbladder Cancer
Primary: Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by…
Adenocarcinoma
Primary: Progression-free Survival (PFS) — 91; 148 days
Biliary Tract Cancer · Biliary Tract Neoplasms
Primary: Overall Response Rate (ORR) After 4 Cycles of Treatment — 22 percent
Cholangiocarcinoma of the Extrahepatic Bile Duct · Cholangiocarcinoma of the Gallbladder · Gastrointestinal Cancer
Primary: Number of Confirmed Tumor Responses. — 6; 0 participants
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Response Rate — 0; 5 percentage of responding patients
Periampullary Cancers With Obstructive Jaundice · Pancreas Head Cancer · Bile Duct Cancer
Primary: Incidence of Infectious Complications After Biliary Drainage — 11; 5 participants
Biliary Tract Cancer
Primary: Percentage of Patients Alive at 1 Year (1-Year Survival Rate) — 39; 31 percentage of participants
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Cancer
Primary: Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at…
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Stage III Intrahepatic Cholangiocarcinoma AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7 · Stage IIIB Gallbladder Cancer AJCC v7
Primary: Median Progression Free Survival (PFS) — 11.4; 14.9 months — p=0.62
Biliary Tract Cancer · Gallbladder Cancer
Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
HER2-amplified Biliary Tract Cancers
Primary: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) — 33; 0 Participants
Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma · Recurrent Adult Liver Carcinoma
Primary: Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 — 0 patients
Biliary Tract Cancer
Primary: Phase Ib: Incidence of Dose-limiting Toxicities (DLTs) of Drug Combination Nanoliposomal-Irinotecan, 5-fluorouracil, Leucovorin and Nivolumab — 4 Participants
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
Metastatic Biliary Tract Carcinoma
Primary: Progression-free Survival (PFS) — 3.58 months
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST — 0 patients
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants
Adult Cholangiocarcinoma · Advanced Adult Hepatocellular Carcinoma · BCLC Stage C Adult Hepatocellular Carcinoma
Primary: Overall Survival — 4.3; 7.9 months — p=0.05